Canada Markets closed

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.04+0.89 (+5.87%)
At close: 04:00PM EST
16.04 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close15.15
Open14.94
Bid15.07 x 1100
Ask24.00 x 800
Day's Range14.14 - 16.31
52 Week Range14.04 - 50.78
Volume126,210
Avg. Volume160,691
Market Cap507.562M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-4.48
Earnings DateMar. 28, 2022 - Apr. 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.83
  • GlobeNewswire

    Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference

    FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate virtually in the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, November 30, 2021 at 9:15 a.m. EST. Members of Phathom’s management team will also participate in one-on-one meetings

  • GlobeNewswire

    Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences

    FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate at two upcoming virtual investor conferences, including: Guggenheim Healthcare Talks: 3rd Annual Neuro/Immunology ConferenceDate: November 16, 2021Live Webcast: 9:40 am EST Jefferies London Hea

  • GlobeNewswire

    Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates

    Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May 3, 2022U.S. launch for both vonoprazan-based treatment regimens for H. pylori anticipated in the second half of 2022, if approvedPositive Phase 3 trial results for vonoprazan in erosive esophagitis (EE) reported in October 2021; NDA submission targeted for the first quarter of 2022 FLORHAM PARK, N.